Patents by Inventor ZIMING WU

ZIMING WU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250011664
    Abstract: A combined hydrogenation process and system for producing chemical raw materials are provided. The process has the following steps: (1) performing a hydrogenation pretreatment reaction on a wax oil raw material and hydrogen-containing gas, mixing the hydrogenated wax oil obtained by means of the reaction and a light diesel oil fraction, and performing a first hydrocracking reaction to obtain a first hydrocracking material flow; (2) separating and fractionating the first hydrocracking material flow to obtain a diesel oil fraction; and (3) performing a second hydrocracking reaction on the diesel oil fraction obtained in step (2) to obtain a second hydrocracking material flow, and separating and fractionating the second hydrocracking material flow. The process can transform all the high aromatics inferior diesel oil raw materials and wax oil raw materials into light naphtha, heavy naphtha tail oil and other high value-added products.
    Type: Application
    Filed: October 14, 2022
    Publication date: January 9, 2025
    Inventors: Siqiang FAN, Zhongyi WANG, Ziming WU, Shaozhong PENG, Chang LIU, Zhengkai CAO, Shike SUN, Zhe CUI
  • Patent number: 11718827
    Abstract: Some embodiments of the disclosure use human peripheral blood for ctDNA sequencing or tumor tissues for whole exome sequencing, screen out mutation sites to perform antigen epitope prediction, connect and synthesize an expression gene sequence of mutant peptides. Other embodiments of the disclosure construct a lentiviral vector, package the lentivirus, transfect an APC cell to complete transformation of a specific LV cell, co-culture in vitro with PBMC separated from the peripheral blood, screen out an effective polypeptide, and transform common T cells into RFF cells. Suppressive signaling molecules include one or more of PD-1, Tim-3, LAG3, CTLA-4, BTLA, VISTA, CD160, and 2B4 (CD244). Antigen presenting cells include one or more of PBMC, a dendritic cell, neutrophil, B lymphocyte, and macrophage.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: August 8, 2023
    Assignees: Beijing DCTY Biotech Co., Ltd.
    Inventors: Shunchang Jiao, Rong Zhang, Tianfu Zhang, Zishan Zhou, Jiasen Xie, Ziming Wu, Gang Peng
  • Publication number: 20210155950
    Abstract: The present invention discloses a gene OsNia3 of a rice nitrate reductase NIA3 protein. The cDNA sequence of the gene is as set out in SEQ ID NO.1, and the rice NIA3 protein encoded by it has an amino acid sequence as set out in SEQ ID NO.2. A homozygous mutant in which the rice gene OsNia3 is knocked out and a homozygous line in which the OsNia3 is over-expressed are obtained by utilizing a transgenic technology. It has been discovered by analysis that the line in which the OsNia3 gene is knocked out has a shortened plant height and a shorted growth period; while the line in which the OsNia3 is over-expressed has a relatively high plant height and a prolonged growth period.
    Type: Application
    Filed: September 28, 2020
    Publication date: May 27, 2021
    Applicant: Jiangxi Agricultural University
    Inventors: Ziming WU, Ruicai HAN, Zhirong XU, Zujun LI, Xunfeng HE, Yongjun ZENG, Yanhua ZENG
  • Publication number: 20200102537
    Abstract: Some embodiments of the disclosure use human peripheral blood for ctDNA sequencing or tumor tissues for whole exome sequencing, screen out mutation sites to perform antigen epitope prediction, connect and synthesize an expression gene sequence of mutant peptides. Other embodiments of the disclosure construct a lentiviral vector, package the lentivirus, transfect an APC cell to complete transformation of a specific LV cell, co-culture in vitro with PBMC separated from the peripheral blood, screen out an effective polypeptide, and transform common T cells into RFF cells. Suppressive signaling molecules include one or more of PD-1, Tim-3, LAG3, CTLA-4, BTLA, VISTA, CD160, and 2B4 (CD244). Antigen presenting cells include one or more of PBMC, a dendritic cell, neutrophil, B lymphocyte, and macrophage.
    Type: Application
    Filed: July 11, 2019
    Publication date: April 2, 2020
    Inventors: SHUNCHANG JIAO, RONG ZHANG, TIANFU ZHANG, ZISHAN ZHOU, JIASEN XIE, ZIMING WU, GANG PENG